Back to top
more

ASLAN Pharmaceuticals (ASLN)

(Delayed Data from NSDQ)

$2.47 USD

2.47
20,509

+0.18 (7.86%)

Updated Jul 11, 2024 03:52 PM ET

After-Market: $2.46 -0.01 (-0.40%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

Ultragenyx Provides Preliminary Crysvita 2019 Revenues

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is ASLAN Pharmaceuticals (ASLN) Outperforming Other Medical Stocks This Year?

Is (ASLN) Outperforming Other Medical Stocks This Year?

Will ASLAN Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.

Will ASLAN Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor ASLAN Pharmaceuticals.

ASLAN Pharmaceuticals Ltd. (ASLN) Moves to Strong Buy: Rationale Behind the Upgrade

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.

Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Top Ranked Momentum Stocks to Buy for March 29th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 29th.

Top Ranked Momentum Stocks to Buy for March 28th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 28th.

ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.